Pelacarsen lowers lipoprotein(a) but does not reduce major cardiovascular events in patients with established cardiovascular disease
1. Pelacarsen reduced levels of lipoprotein(a) by 77.7%, but did not change the incidence of major adverse cardiovascular events compared ...








![2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]](https://www.2minutemedicine.com/wp-content/uploads/2025/05/pharma-roundup-may-12-2025-350x250.png)
